Publications

*Co-corresponding authors

​# Equal contribution

​

Cheung TT#*, Ho DW#, Lyu SX#; Zhang QY, Tsui YM, Yu TC, Sze KM, Lee JM, Lau VW, Chu EY, Tsang SH, She WH, Leung RC, Yau TC*, Ng IO*. Multimodal integrative genomics and pathology analyses in neoadjuvant nivolumab treatment for intermediate and locally advanced hepatocellular carcinoma. Liver Cancer 2023; May 23.

 

Huang H#, Tsui YM#, Ho DW, Chung CY, Sze KM, Lee E, Cheung GC, Zhang VX, Wang X, Lyu X, Ng IO. LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress.  Hepatology 2023 Aug 7.

​

Wang X, Huang HY, Sze KM, Wang J, Tian L, Lu JY, Tsui YM, Ma HT, Lee E, Chen A, Lee JM, Wang Y, Yam JW, Cheung TT, Guan XY, Ng IO. S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos. Gut 2023; Jan 11:gutjnl-2022-327998.

​

Huang H#, Tsui YM#, Ng IO. Fueling HCC dynamics: interplay between tumor microenvironment and tumor initiating cells. Cell Mol Gastroenterol Hepatol 2023; Feb 2;15(5):1105-1116.

​

Chiu YT#, Husain A#, Sze KM, Ho DW, Suarez EM, Wang X, Lee E, Ma HT, Lee JM, Chan LK, Ng IO. Mid-line 1 interacting protein 1 promotes cancer metastasis via FOS like 1-mediated matrix metalloproteinase 9 signaling in HCC. Hepatology 2023; Jan 13. Online ahead of print.

​

Kam CS, Ho DW, Ming VS, Tian L, Zhang VX, Tsui YM, Lee JM, Wong CC, Chan AC, Cheung TT, Chan LK*, Ng IO*. PFKFB4 drives the oncogenicity in TP53-mutated hepatocellular carcinoma in a phosphatase-dependent manner. Cell Mol Gastroenterol Hepatol 2023; Feb 16:S2352-345X(23)00023-1. 

​

Zhang QY, Ho DW, Tsui YM, Ng IO. Single-Cell Transcriptomics of Liver Cancer: Hype or Insights? Cell Mol Gastroenterol Hepatol. 2022;14(3):513-525. doi: 10.1016/j.jcmgh.2022.04.014. Epub 2022 May 14. 

 

Wang X, Tian L, Lu J, Ng IO. Exosomes and cancer - Diagnostic and prognostic biomarkers and therapeutic vehicle. Oncogenesis. 2022 Sep 15;11(1):54. doi: 10.1038/s41389-022-00431-5.

​

Husain A, Chiu YT, Sze KM, Ho DW, Tsui YM, Suarez EMS, Zhang VX, Chan LK, Lee E, Lee JM, Cheung TT, Wong CC, Chung CY, Ng IO. Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma. J Hepatol. 2022 Feb 25:S0168-8278(22)00125-8.

​

Tian L#, Zhao L#, Sze KM#, Kam CS, Ming VX, Wang X, Zhang VX, Ho DW, Chan LK*, Ng IO*. Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma. Hepatology 2022; 76:48-65.

​

Lyu X, Tsui YM, Ho DW, Ng IO. Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol. 2022;13(6):1611-1624. doi: 10.1016/j.jcmgh.2022.02.008. Epub 2022 Feb 17.  

 

Ho DW*, Tsui YM, Chan LK, Sze KM, Zhang X, Cheu JW, Chiu YT, Lee JM, Chan AC, Cheung ET, Yau DT, Chia NH, Lo IL, Sham PC, Cheung TT, Wong CC, Ng IO*. Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nat Commun. 2021 Jun 17;12(1):3684.

​

Zhang VX, Sze KM, Chan LK, Ho DW, Tsui YM, Chiu EY, Lee E, Husain A, Huang HY,Tian L, Wong CC, Ng IO. Antioxidant supplements promote tumor formation and growth and confer drug resistance in hepatocellular carcinoma by reducing intracellular ROS and induction of TMBIM1. Cell & Bioscience 2021 Dec 19;11(1):217.

​ 

Khandakar B, Liu JR, Thung S, Li Y, Rhee HJ, Kagen AC, Tong TS, Park YN*, Theise N*, Ng IO*. Lymphoepithelioma-like neoplasm of the biliary tract with ‘probable low malignant potential. Histopathology 2021 Oct 5.

​

Wang X, Wang J, Tsui YM, Shi C, Wang Y, Zhang X, Yan Q, Chen M, Jiang aC, Yuan YF, Wong CM, Liu M, Feng ZY, Chen H, Ng IOL, Jiang L, Guan XY. RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-β2. Nat Commun. 2021 Mar 9;12(1):1518.

 

Chan LK, Ho DW, Kam CS, Chiu EY, Lo IL, Yau DT, Cheung ET, Tang CN, Tang VW, Lee TK, Wong CC, Chok KS, Chan AC, Cheung TT, Wong CM, Ng IO. RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma. J Hepatol. 2021 Feb;74(2):360-371.

 

Chan LK, Tsui YM, Ho DW, Ng IO. Cellular heterogeneity and plasticity in liver cancer. Semin Cancer Biol. 2021 Feb 26:S1044-579X(21)00050-X.

 

Sze KM, Ho DW, Chiu YT, Tsui YM, Chan LK, Lee JM, Chok KS, Chan AC, Tang CN, Tang VW, Lo IL, Yau DT, Cheung TT, Ng IO. Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma. Hepatology. 2021 Jan;73(1):23-40.

 

Tsui YM, Chan LK, Ng IO. Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential. Br J Cancer. 2020 May;122(10):1428-1440.

 

Chan LK, Ng IO. Joining the dots for better liver cancer treatment. Nat Rev Gastroenterol Hepatol 2020; 17:74-75.

 

Ho DW#, Tsui YM#, Sze KM, Chan LK, Cheung TT, Lee E, Sham PC, Tsui SK, Lee TK, Ng IO. Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer. Cancer Lett 2019; 459:176-185.

 

Tsang FH, Law CT, Tang CT, Cheng CL, Chin DW, Tam VW, Wei L, Wong CC, Ng IO*, Wong CM*. Aberrant super-enhancer landscape in human hepatocellular carcinoma. Hepatology 2019; 69:2502-2517.

 

Lee D, Xu IM, Chiu DK, Leibold J, Tse AP, Chan CY, Lai RK, Cheung TT, Chok SH, Wong CM, Lowe S, Ng IO*, Wong CC*. Induction of oxidative stress via inhibition of thioredoxin reductase 1 is an effective therapeutic approach for hepatocellular carcinoma. Hepatology 2019; 69:1768-1786.

 

Ma W#, Ho DW#, Sze KM#, Tsui YM, Chan LK, Lee JM, Ng IO. APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity. Mol Carcinog 2019; 58:643-653.

 

Wong CM#, Tsang FH#, Ng IO. Regulatory RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol 2018; 15:137-151.

 

Cheng BY, Lau EY, Leung DH, Ho NP, Cheng LK, Ma S, Lin CH, Lo RC, Ng IO*, Lee TK*. IRAK1 augments cancer stemness and drug resistance via the AP-1/AKR1B10 signaling cascade in hepatocellular carcinoma. Cancer Res 2018; 78:2332-2342.

 

Ho DW#, Chan LK#, Chiu EY, Xu IM, Poon RT, Cheung TT, Lo IL, Lam PW, Tang CN, Tang VW, Yau DT, Li MX, Wong CM, Ng IO. Exome and targeted sequencing identifies frequent TSC 1 and 2 mutations in HBV-associated hepatocellular carcinoma with high sensitivity to mTOR inhibitor treatment. Gut 2017; 66:1496-1506.

 

Cui CP, Wong CC, Kai AK, Ho DW, Lau EY, Tsui YM, Chan LK, Cheung TT, Chok KS, Chan AC, RC Lo, Lee JM, Lee TK, Ng IO. SENP1 promotes hypoxia-induced cancer stemness by HIF-1α deSUMOylation and SENP1/HIF-1α positive feedback loop. Gut 2017; 2017; 66:2149-2159.

 

Ma MK#, Lau EY#, Lo J, Ho NP, Ma S, Lin CH, Copland JA, Ding J, Lo RC, Ng IO*, Lee TK*. Targeting liver-tumor initiating cells via hampering Stearoyl-CoA Desaturase (SCD1) mediated ER stress. J Hepatol 2017; 67:979-990.

 

Xu IM, Lai RK, Lin SH, Tse AP, Chiu DK, Koh HY, Law CT, Wong CM, Cai ZW, Wong CC*, Ng IO*. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci USA 2016;113:E725-34.

 

Kai AK, Chan LK, Lo RC, Lee JM, Wong CC, Wong CM, Ng IO. Downregulation of TIMP2 via HIF-1/ miR-210/HIF-3 regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology 2016; 64:473-87.

 

Chiu YT#, Wong JK#, Choi SW, Sze KM, Ho DW, Chan LK, Man K, Cherny S, Yang WL, Wong CM*, Sham PC*, Ng IO*. Novel pre-mRNA splicing of intronic integrated HBV in generation of oncogenic chimera in hepatocellular carcinoma. J Hepatol 2016; 64: 1256-64.

 

Wong CM*, Lai W, Law CT, Ho DW, Tsang FH, Au SL, Sze KM, Lee JM, Wong CC, Ng IO*. Upregulation of histone methyltransferase SETDB1 expression by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. Hepatology 2016; 63:474-87.

 

Lo J, Lau EY, Ching RH, Ng IO*, Lee TK*. NF-KB mediated CD47 upregulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma. Hepatology 2015; 62: 534–545.

 

Lee TK*#, Cheung VC#, Lu P, Lau EY, Ma S, Tang KH, Tong C, Ng IO*. Blockade of CD47 mediated CTSS-PAR2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 2014;60:179-91.

 

Wong CC, Tse AP, Huang YP, Zhu YT, Chiu DK, Au SL, Kai AK, Lee JM, Wei LL, Tsang FH, Lo RC, Shi J, Zheng YP, Wong CM, Ng IO. Deregulation of Lysyl Oxidase-Like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma metastasis. Hepatology 2014; 60:1645-58.

 

Sze KM, Chu GK, Mak QH, Lee JM, Ng IO. Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of MAD1 and has suppressive role in mitotic checkpoint signaling in HCC. J Pathol 2014; 233:51-60.

 

Wong CM#, Wong CC#, Lee JMF, Fan DNY, Au SLK, Ng IO. Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 2012; 55:1453-61.  (Featured on cover) (Faculty of 1000 (F1000) - the top 2% of published articles in biology and medicine).

 

Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO*. CD24+ liver tumor-initiating cells drive self-renewal and tumor initiation through Stat3-mediated nanog regulation. Cell Stem Cell 2011; 9:50-63.

 

Wong CC, Wong CM, Tung EKK, Au SLK, Lee JMF, Man K, Ng IO. MiR-139 suppresses metastasis and progression of hepatocellular carcinoma through regulation of Rho-kinase 2 (ROCK2). Gastroenterology 2011;140:322-31. (Top 2% of published articles in biology and medicine, Faculty of 1000).

 

Sze KM#, Wong KL#, Chu GK, Yau TO, Ng IO. Loss of PTEN enhances cell invasion and migration through AKT/Sp-1 transcription factor/MMP2 activation and has clinicopathologic significance in hepatocellular carcinoma. Hepatology 2011;53:1558-69.

 

Chan DW, Chan CY, Yam JWP, Ching YP, Ng IO. Prickle-1 promotes degradation of Dishevelled by ubiquitination in liver cancer. Gastroenterology 2006; 131:1218-27.

 

Leung TH, Ching YP, Yam JW, Wong CM, Yau TO, Jin DY, Ng IO. Deleted in liver cancer 2, DLC2, suppresses cell transformation via inhibition of RhoA activity. Proc Natl Acad Sci USA 2005;102;15207-12.

 

Wong CM, Yam JW, Ching YP, Leung TH, Yau TO, Jin DY, Ng IO. Rho GTPase activating protein DLC1 (deleted in liver cancer) suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 2005; 65: 8861-8868.